Sanofi India Past Earnings Performance
Past criteria checks 3/6
Sanofi India has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 1.9% per year. Sanofi India's return on equity is 77.5%, and it has net margins of 18.8%.
Key information
4.7%
Earnings growth rate
4.7%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -1.9% |
Return on equity | 77.5% |
Net Margin | 18.8% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up
Jun 11Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 26Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00
Apr 12Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00
Mar 29Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00
Mar 09Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)
Dec 21Is Sanofi India (NSE:SANOFI) A Risky Investment?
May 26Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?
May 10Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Apr 02Sanofi India (NSE:SANOFI) Is Increasing Its Dividend To ₹490
Feb 25Estimating The Fair Value Of Sanofi India Limited (NSE:SANOFI)
Dec 10Revenue & Expenses Breakdown
How Sanofi India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 28,225 | 5,304 | 3,908 | 0 |
30 Jun 24 | 27,893 | 5,288 | 4,055 | 0 |
31 Mar 24 | 28,470 | 5,491 | 4,132 | 0 |
31 Dec 23 | 28,511 | 6,029 | 4,126 | 0 |
30 Sep 23 | 28,291 | 5,961 | 4,178 | 0 |
30 Jun 23 | 28,064 | 5,751 | 4,219 | 0 |
31 Mar 23 | 27,996 | 5,726 | 4,323 | 0 |
31 Dec 22 | 27,701 | 6,206 | 4,414 | 0 |
30 Sep 22 | 27,861 | 5,801 | 4,603 | 0 |
30 Jun 22 | 28,487 | 9,790 | 4,704 | 0 |
31 Mar 22 | 29,385 | 10,369 | 4,783 | 0 |
31 Dec 21 | 29,566 | 9,444 | 4,836 | 0 |
30 Sep 21 | 29,890 | 9,770 | 4,885 | 0 |
30 Jun 21 | 29,211 | 5,801 | 4,907 | 0 |
31 Mar 21 | 28,425 | 5,381 | 5,024 | 0 |
31 Dec 20 | 29,019 | 4,776 | 5,164 | 0 |
30 Sep 20 | 30,079 | 4,519 | 5,635 | 0 |
30 Jun 20 | 31,004 | 4,456 | 5,709 | 0 |
31 Mar 20 | 31,378 | 4,067 | 4,664 | 0 |
31 Dec 19 | 30,706 | 4,142 | 5,446 | 0 |
30 Sep 19 | 29,707 | 3,962 | 5,269 | 0 |
30 Jun 19 | 29,354 | 3,888 | 5,145 | 0 |
31 Mar 19 | 28,704 | 3,910 | 5,008 | 0 |
31 Dec 18 | 27,708 | 3,806 | 4,928 | 0 |
30 Sep 18 | 26,870 | 3,773 | 4,773 | 0 |
30 Jun 18 | 26,107 | 3,744 | 4,694 | 0 |
31 Mar 18 | 25,284 | 3,485 | 4,639 | 0 |
31 Dec 17 | 24,636 | 3,260 | 4,576 | 0 |
30 Sep 17 | 23,747 | 2,953 | 4,426 | 0 |
30 Jun 17 | 23,454 | 2,619 | 4,393 | 0 |
31 Mar 17 | 23,650 | 2,744 | 4,288 | 0 |
31 Dec 16 | 23,668 | 3,042 | 4,221 | 0 |
30 Sep 16 | 23,452 | 2,989 | 4,242 | 0 |
30 Jun 16 | 23,068 | 2,909 | 4,118 | 0 |
31 Mar 16 | 22,486 | 2,699 | 3,382 | 0 |
31 Dec 15 | 21,931 | 2,377 | 4,000 | 0 |
30 Sep 15 | 21,363 | 2,111 | 6,231 | 0 |
30 Jun 15 | 20,654 | 2,005 | 6,136 | 0 |
31 Mar 15 | 20,215 | 1,938 | 6,052 | 0 |
31 Dec 14 | 19,775 | 1,971 | 3,555 | 0 |
30 Sep 14 | 19,539 | 2,384 | 5,582 | 0 |
30 Jun 14 | 19,364 | 2,534 | 5,471 | 0 |
31 Mar 14 | 18,657 | 2,471 | 5,389 | 0 |
31 Dec 13 | 18,089 | 2,398 | 5,320 | 0 |
Quality Earnings: SANOFI has high quality earnings.
Growing Profit Margin: SANOFI's current net profit margins (18.8%) are lower than last year (21.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SANOFI's earnings have grown by 4.7% per year over the past 5 years.
Accelerating Growth: SANOFI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SANOFI had negative earnings growth (-11%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: SANOFI's Return on Equity (77.5%) is considered outstanding.